Get the Stockscreener App
0.00
100.00%
-54.65
Akero Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
See More
Previous Close:
$54.65
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$4.50B
Revenue:
-
Net Income/Loss:
$-269.44M
P/E Ratio:
0.00
EPS:
-3.75
Net Cash Flow:
$-262.63M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$57.35
Akero Therapeutics Inc Stock (AKRO) Company Profile
Name
Akero Therapeutics Inc
Sector
Industry
Phone
650-487-6488
Address
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Compare AKRO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
0.00 | 4.50B | 0 | -269.44M | -262.63M | -3.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.87 | 121.26B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.28 | 83.04B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
828.24 | 50.22B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.00 | 43.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
348.85 | 39.16B | 4.98B | 69.60M | 525.67M | 0.5198 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Aug-04-25 | Initiated | TD Cowen | Buy |
| Jan-30-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-27-25 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-24 | Initiated | Citigroup | Buy |
| Apr-22-24 | Resumed | BofA Securities | Neutral |
| Sep-19-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-23 | Initiated | UBS | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-14-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| Feb-26-21 | Initiated | Guggenheim | Buy |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Jul-20-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-07-20 | Initiated | Chardan Capital Markets | Buy |
| Jul-01-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-02-20 | Initiated | H.C. Wainwright | Buy |
| Feb-10-20 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Evercore ISI | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
| Jul-15-19 | Initiated | Jefferies | Buy |
| Jul-15-19 | Initiated | ROTH Capital | Buy |
View All
Akero Therapeutics Inc Stock (AKRO) Latest News
Akero Therapeutics, Inc. (AKRO) Stock Analysis: Navigating Growth in Biotechnology with a 3.39% Potential Upside - DirectorsTalk Interviews
Behavioral Patterns of AKRO and Institutional Flows - Stock Traders Daily
Analyst Calls: Is Akero Therapeutics Inc stock showing strong momentumPortfolio Growth Summary & AI Powered Market Trend Analysis - baoquankhu1.vn
Aug Movers: Is Akero Therapeutics Inc. stock influenced by commodity prices2025 Support & Resistance & Momentum Based Trading Ideas - mfd.ru
Akero Therapeutics, Inc. (AKRO) Stock Analysis: Exploring the 3.39% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Does Akero Therapeutics Inc. have consistent dividend growth2025 Price Targets & Weekly Watchlist for Hot Stocks - mfd.ru
Investment Report: Will Akero Therapeutics Inc outperform the market in YEARJuly 2025 Analyst Calls & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Income Plays: Is INTU a stock for growth or value investorsJuly 2025 Rallies & Expert-Curated Trade Recommendations - baoquankhu1.vn
Guidance Update: What is the earnings history of Akero Therapeutics Inc2025 Volume Leaders & Safe Capital Growth Tips - baoquankhu1.vn
(AKRO) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Quarterly Trades: How does ProShares Trust ProShares UltraPro Short QQQ perform in inflationary periodsJuly 2025 Action & High Accuracy Buy Signal Tips - baoquankhu1.vn
In Vivo’s Deals Of The Year: Cast Your Vote! - Citeline News & Insights
RSI Check: Does Akero Therapeutics Inc meet Warren Buffetts criteriaJuly 2025 Momentum & Stepwise Trade Signal Guides - baoquankhu1.vn
Sentiment Recap: Does Akero Therapeutics Inc meet Warren Buffetts criteriaWeekly Risk Report & Smart Swing Trading Alerts - baoquankhu1.vn
Akero Therapeutics shareholders approve Novo Nordisk merger - MSN
December blockbusters push biopharma deal value to record high - BioWorld MedTech
Q4 Activity Finishes Off Stronger Biopharma M&A Year In 2025 - Citeline News & Insights
Aug Technicals: Is CKX Lands Inc a potential multi baggerMarket Activity Recap & Daily Profit Focused Stock Screening - baoquankhu1.vn
Inflation Data: Is ISPC still a buy after recent gainsJuly 2025 EndofMonth & Long-Term Safe Return Strategies - baoquankhu1.vn
Published on: 2026-01-14 06:28:29 - Bộ Nội Vụ
Insider Buy: What is Akero Therapeutics Incs revenue forecastJuly 2025 Earnings & Safe Capital Investment Plans - baoquankhu1.vn
Akero Therapeutics, Inc. (AKRO) Stock Analysis: Navigating the Biotech’s 3.39% Potential Upside - DirectorsTalk Interviews
AKRO stock hits 52-week high, soaring to $56.86 - MSN
Why Akero Therapeutics Inc (AKRO) Is Skyrocketing So Far In 2025 - MSN
Aug Gainers: Will Akero Therapeutics Inc. stock see PE expansionFed Meeting & Daily Oversold Stock Bounce Ideas - Улправда
How Akero Therapeutics Inc. stock performs in rising dollar environmentEarnings Growth Report & Fast Entry and Exit Trade Plans - Улправда
Can Akero Therapeutics Inc. stock resist sector downturnsTrade Volume Summary & Reliable Intraday Trade Plans - Улправда
Akero Therapeutics, Inc. (AKRO) Stock Analysis: Potential 3.39% Upside In Biotech Innovation - DirectorsTalk Interviews
Medical Stocks To Add to Your WatchlistDecember 15th - MarketBeat
Akero Therapeutics Earnings Notes - Trefis
Top Mid Cap Stocks To Add to Your WatchlistDecember 16th - MarketBeat
Best Medical Stocks To Follow NowDecember 10th - MarketBeat
Bank Watch: Will Akero Therapeutics Inc stock see PE expansionBond Market & Weekly Momentum Picks - moha.gov.vn
Best Medical Stocks To Watch NowDecember 9th - MarketBeat
Akero Therapeutics, Inc. (AKRO) Stock Analysis: Unpacking the Upside Potential in Transformative Biotech - DirectorsTalk Interviews
Revenue Check: Will Akero Therapeutics Inc stock split again soonJuly 2025 Summary & High Return Trade Guides - moha.gov.vn
Why Akero Therapeutics Inc. stock could benefit from AI revolutionWall Street Watch & Long-Term Safe Investment Ideas - Улправда
Price Action: Is Akero Therapeutics Inc. stock a safe haven assetSell Signal & Daily Profit Focused Stock Screening - Улправда
Is Akero Therapeutics Inc. stock a safe haven assetJuly 2025 Movers & Reliable Intraday Trade Alerts - Улправда
History Review: Will Akero Therapeutics Inc. stock see PE expansion2025 Technical Patterns & Daily Oversold Stock Bounce Ideas - DonanımHaber
Will Akero Therapeutics Inc. stock split again soonStock Surge & Intraday High Probability Alerts - DonanımHaber
Is Akero Therapeutics Inc. stock cheap at current valuationJuly 2025 Macro Moves & Weekly High Potential Stock Alerts - Улправда
Best Medical Stocks To Follow TodayDecember 12th - MarketBeat
Top Mid Cap Stocks To Follow NowDecember 12th - MarketBeat
Promising Mid Cap Stocks To Watch NowDecember 11th - MarketBeat
Hudson Bay Capital Management LP Buys 84,573 Shares of Akero Therapeutics, Inc. $AKRO - MarketBeat
Frazier Life Sciences Management L.P. Acquires New Shares in Akero Therapeutics, Inc. $AKRO - MarketBeat
Hudson Bay Capital Management LP Acquires 84,573 Shares of Akero Therapeutics, Inc. $AKRO - MarketBeat
Akero Therapeutics, Inc. Financial Disclosures & Filings - TradingView — Track All Markets
General Atlantic L.P. Acquires 500,000 Shares of Akero Therapeutics, Inc. $AKRO - MarketBeat
Akero Therapeutics, Inc. Stock ()Quote BOERSE BERLIN - marketscreener.com
Akero Therapeutics Inc Stock (AKRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.10%
7.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):